Subscribe
brown-eye-close-up
5 August 2013Big Pharma

Roche signs drug licensing agreement with MPP

On August 5, Swiss pharmaceutical company Roche signed an agreement with the Medicines Patent Pool (MPP) to increase access to its drug valganciclovir (Valcyte), an oral medicine for the treatment of preventable viral infection cytomegalovirus (CMV).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
ViiV Healthcare joins patent pool for cheaper AIDS drugs
28 February 2013   ViiV Healthcare, a public health joint venture between GlaxoSmithKline, Shionogi and Pfizer, has signed up to the Medicines Patent Pool (MPP) to provide greater access to affordable AIDS treatments in developing countries.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
ViiV Healthcare joins patent pool for cheaper AIDS drugs
28 February 2013   ViiV Healthcare, a public health joint venture between GlaxoSmithKline, Shionogi and Pfizer, has signed up to the Medicines Patent Pool (MPP) to provide greater access to affordable AIDS treatments in developing countries.

More on this story

Big Pharma
ViiV Healthcare joins patent pool for cheaper AIDS drugs
28 February 2013   ViiV Healthcare, a public health joint venture between GlaxoSmithKline, Shionogi and Pfizer, has signed up to the Medicines Patent Pool (MPP) to provide greater access to affordable AIDS treatments in developing countries.

More features

Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages
Judge denies Intellia bid to throw out suit over $100m Regeneron pact
‘AI curious’ counsel at AZ, Novartis weigh risks and benefits
Trump’s return sparks calls for pro-patent agenda
EOFlow ordered to pay rival $452m over insulin patch trade secrets
Amgen faces pushback over bid to narrow patent scope